Thursday 22nd June 2023
SRUK reveals results of survey of Rheumatologists
SRUK Calls for greater investment in rare rheumatic disease training as survey finds Rheumatologists can struggle due to lack of education and resource
Wednesday 29th June 2022
Undiagnosed & Untreated: Realities of Systemic Sclerosis in Europe Today
Tuesday 28th June 2022
‘Olive Ayoub Intermediate to Late-Stage Post-Doctoral Research Fellowship’ Opens for Applications on 29th June
On 29th June, Scleroderma & Raynaud’s UK will open applications for the Olive Ayoub Intermediate to Late-Stage Post-doctoral Research Fellowship, which will enable one exceptional, non-tenured post-doctoral researcher to transition from postdoc to research leader in the field of scleroderma.
Friday 24th June 2022
Identifying Scleroderma Patients at Risk of Pulmonary Hypertension - US Study Provides Potential Biomarker for the Condition
A new US study has found that scleroderma patients who test positive for ‘anti-Th/To antibodies’ are at higher risk of developing pulmonary hypertension (PH) in comparison to other patients, which could enable the earlier detection and more effective management of one of scleroderma’s most serious complications.
Friday 17th June 2022
Mum Whose Daughters Have Scleroderma Helps SRUK Produce Schools Guide
Both of Alison's daughters have scleroderma, and having experienced the lack of understanding around the condition, she set out to help SRUK create a guide to scleroderma for schools.
Wednesday 8th June 2022
Innovative Medicines Fund: Accelerating treatments to the rare disease community
Yesterday saw the launch of the Innovative Medicines Fund (IMF) - a scheme which will give NHS patients living in England, including those with rare diseases like Scleroderma, the chance to have ‘early’ access to cutting-edge treatments offering them the best chances of a longer and healthier life.
Thursday 24th June 2021
The CRISTAL Index
SRUK funding is playing a key role in improving how we determine the success of new treatments in clinical trials. These projects aim to better inform researchers of the impact of potential therapies, ultimately improving wellbeing and quality of life for people living with scleroderma.
Friday 11th June 2021
Walk for SRUK
People across the UK are being invited to lace up their trainers and get walking this summer in aid of people living with a chronic, life-limiting autoimmune condition called scleroderma
Thursday 10th June 2021
SRUK joins call for employers to support people who may have less protection from vaccines
A coalition of charities, including SRUK has written an open letter to employers, calling for them to put protective measures in place for staff who may have reduced protection from the COVID-19 vaccine.
Friday 26th June 2020
New findings on lenabasum from RESOLVE-1 trial
Lenabasum is a synthetic drug that activates a certain receptor involved in the immune system and in the activity of fibroblasts, which drive fibrosis (scarring), and is particularly useful for diffuse cutaneous scleroderma.